All In Biotech

Drug Trial Radar · NCT06494501

The Prevent Coronary Artery Disease Trial

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,600

Planned (sponsor's estimate)

Start

Sep 12, 2024

Primary completion

Jun 30, 2032

Study completion Jun 30, 2032

Sponsor

Lead sponsor
Icahn School of Medicine at Mount SinaiAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Despite increasing evidence that exposure to cardiovascular risk factors (CVRF) at an early age increases the prevalence of subclinical atherosclerosis and is associated with a greater risk of cardiovascular events later in life, there is a lack of randomized trial evidence to support primary prevention strategies in adults aged 30-50 years. The researchers have designed a randomized controlled trial to evaluate whether strict control of CVRF in young adults without known cardiovascular disease, will reduce the progression of total atherosclerosis burden, a surrogate endpoint for symptomatic cardiovascular disease, compared with usual care. The researchers propose a randomized controlled trial enrolling 1,600 healthy young adults who meet the inclusion criteria and who do not meet any exclusion criteria. Eligible study participants will be randomized, in a 1:1 ratio, to either the intervention group (active treatment strategy) or to the control group (guideline-directed medical therapy). Randomization will be stratified by the presence or absence of atherosclerotic plaque in vascular ultrasound.

Conditions

  • Atherosclerotic Cardiovascular Disease

Interventions

  • InclisiranDrug

    Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in atherosclerotic plaque burden from baselineTime frame: Baseline, 2.5 years and 5 years after randomization

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mount Sinai Fuster Heart Hospital

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.